Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
89
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer

Tetsuo Tani1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;2 Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan;3 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-5719-2697
ORCID Icon,
Ichiro Nakachi1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;4 Department of Internal Medicine, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3930-9318
ORCID Icon,
Shinnosuke Ikemura1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan
,
Shigenari Nukaga1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;5 Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan
,
Keiko Ohgino1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;6 Department of Pulmonary Medicine, Kawasaki Municipal Hospital, Kawasaki, Kanagawa, Japan
,
Aoi Kuroda1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;7 Department of Respiratory Medicine, Tokyo Dental College Ichikawa General Hospital, Chiba, Japan
,
Hideki Terai1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;8 Department of Pulmonary Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
,
Keita Masuzawa1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;8 Department of Pulmonary Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
,
Taro Shinozaki1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan
,
Kota Ishioka1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;9 Department of Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan
,
Yohei Funatsu1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;2 Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan
,
Hidefumi Koh1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;2 Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan
,
Koichi Fukunaga1 Department of Medicine, Keio University School of Medicine, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-7460-1990
ORCID Icon,
Kenzo Soejima1 Department of Medicine, Keio University School of Medicine, Tokyo, Japan;10 Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan
& On behalf of the Keio Lung Oncology Group (KLOG) show all
Pages 7497-7503 | Published online: 29 Sep 2021

References

  • SiegelRL, MillerKD, JemalA. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.30620402
  • RiihimakiM, HemminkiA, FallahM, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86:78–84. doi:10.1016/j.lungcan.2014.07.02025130083
  • SatoT, SoejimaK, FujisawaD, et al. Prognostic understanding at diagnosis and associated factors in patients with advanced lung cancer and their caregivers. Oncologist. 2018;23:1218–1229. doi:10.1634/theoncologist.2017-032930120158
  • Rybarczyk-KasiuchniczA, RamlauR, StencelK, et al. Treatment of brain metastases of non-small cell lung carcinoma. Int J Mol Sci. 2021;22:593.
  • HaasAR, StermanDH, MusaniAI. Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach. Chest. 2007;132:1036–1041. doi:10.1378/chest.06-175717873197
  • MorgenszternD, WaqarS, SubramanianJ, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7:1485–1489. doi:10.1097/JTO.0b013e318267223a22982649
  • HananeK, SalmaB, KhadijaB, et al. Peritoneal carcinomatosis, an unusual and only site of metastasis from lung adenocarcinoma. Pan Afr Med J. 2016;23:60. doi:10.11604/pamj.2016.23.60.891027217885
  • SuHT, TsaiCM, PerngRP. Peritoneal carcinomatosis in lung cancer. Respirology. 2008;13(3):465–467. doi:10.1111/j.1440-1843.2008.01268.x18399874
  • PatilT, AisnerDL, NoonanSA, et al. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer. 2016;96:27–32. doi:10.1016/j.lungcan.2016.03.00727133746
  • AbbateMI, CortinovisDL, TiseoM, et al. Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review. Future Oncol. 2019;15(9):989–994. doi:10.2217/fon-2018-046930681378
  • SperdutoPW, KasedN, RobergeD, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–425. doi:10.1200/JCO.2011.38.052722203767
  • SatohH, IshikawaH, YamashitaYT, et al. Peritoneal carcinomatosis in lung cancer patients. Oncol Rep. 2001;8:1305–1307.11605054
  • KobayashiM, SakamotoJ, NamikawaT, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol. 2006;12:1412–1415. doi:10.3748/wjg.v12.i9.141216552811
  • KashiwabaraK, FujiS, TsumuraS, et al. Prognosis of EGFR-mutant lung adenocarcinoma patients with malignant pleural effusion receiving first-line EGFR-TKI therapy without pleurodesis: a Single-institute Retrospective Study. Anticancer Res. 2020;40:1117–1121. doi:10.21873/anticanres.1405132014962
  • YangJ, LeeOJ, SonSM, et al. EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors. Cancer Res Treat. 2018;50:908–916. doi:10.4143/crt.2017.37828934846
  • SetoT, KatoT, NishioM, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, Phase 2 study. Lancet Oncol. 2014;15:1236–1244. doi:10.1016/S1470-2045(14)70381-X25175099
  • NassereddineH, SannierA, BrosseauS, et al. Clinicopathological and Molecular Study of peritoneal carcinomatosis associated with non-small cell lung carcinoma. Pathol Oncol Res. 2020;26:2795–2800. doi:10.1007/s12253-019-00713-131407221

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.